Broad Molecular Profiling Panels For Hematologic Malignancies and Myeloid Malignancy Panels

- I. Broad molecular profiling panels for hematologic malignancies and myeloid malignancy panels in bone marrow or peripheral blood (81450, 81455) are considered **medically necessary** when:
 - A. The member has blood work (CBC) and bone marrow evaluation which are consistent with acute myeloid leukemia (AML), **OR**
 - B. The member has newly diagnosed acute lymphoblastic leukemia (ALL), **OR**
 - C. The member has newly diagnosed <u>myelodysplastic syndrome</u> (MDS), **OR**
 - D. The member has suspected <u>myelodysplastic syndrome</u> (MDS) and other causes of cytopenia(s) have been ruled out, **OR**
 - E. The member is suspected to have a <u>myeloproliferative neoplasm</u> (MPN), **AND**
 - 1. This is the member's initial genetic evaluation for suspected MPN, **OR**
 - 2. Previous results of *JAK2*, *CALR*, and *MPL* analysis were negative, **OR**
 - F. The member has a diagnosis of chronic myelogenous leukemia (CML), **AND**
 - 1. There has been progression to accelerated or blast phase, **OR**
 - 2. Results of *BCR-ABL1* kinase domain mutation analysis were negative.
- II. Repeat broad molecular profiling panels for hematologic malignancies and myeloid malignancy panels in bone marrow or peripheral blood (81450, 81455) are considered **medically necessary** when:
 - A. The member has myelodysplastic syndrome (MDS), AND



Effective: 1/1/2024

Last Review: 9/1/2023

- The member has relapsed after allo-HCT [hematopoietic cell transplant], OR
- B. The member has acute lymphoblastic leukemia (ALL), **AND**
 - The member is showing evidence of symptomatic relapse after maintenance therapy, OR
- C. The member has acute myeloid leukemia (AML), AND
 - 1. The member has relapsed or refractory disease or progression on treatment.
- III. Broad molecular profiling panels for hematologic malignancies and myeloid malignancy panels in bone marrow or peripheral blood (81450, 81455) are considered investigational for all other indications.

Note: If a multigene panel is performed, appropriate panel codes should be used. These clinical criteria are not intended to address liquid biopsies.

NOTES AND DEFINITIONS

1. **Myeloproliferative Neoplasms** are rare overlapping blood diseases in which the bone marrow makes too many red blood cells, white blood cells, or platelets.

There are seven subcategories of myeloproliferative neoplasms:

- Chronic myeloid leukemia (CML)
- Polycythemia vera (PV)
- Primary myelofibrosis (PMF)
- Essential thrombocytopenia (ET)
- Chronic neutrophilic leukemia
- Chronic eosinophilic leukemia
- Chronic eosinophilic leukemia-not otherwise specified
- MPN, unclassifiable (MPN-U)
- 2. **Myelodysplastic Syndromes (MDS)** are a group of disorders characterized by abnormalities of the bone marrow, leading to low numbers of one or more types of blood cells. The WHO system recognizes 6 main types of MDS:



Effective: 1/1/2024

Last Review: 9/1/2023

- MDS with multilineage dysplasia (MDS-MLD)
- MDS with single lineage dysplasia (MDS-SLD)
- MDS with ring sideroblasts (MDS-RS)
- MDS with excess blasts (MDS-EB)
- MDS with isolated del(5q)
- MDS, unclassifiable (MDS-U)

REFERENCES

- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Version 1.2023 https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 4.2023. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. Version 1.2023 https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Chronic Myeloid Leukemia. Version 1.2024. https://www.nccn.org/professionals/physician_qls/pdf/cml.pdf
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Acute Lymphoblastic Leukemia. Version 2.2023. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf



Effective: 1/1/2024

Last Review: 9/1/2023